Sleep Apnea Treatments Beyond CPAP: What Actually Works When You Cannot Tolerate the Mask

Research-informed explainer — last updated April 12, 2026

CPAP is the most effective treatment for obstructive sleep apnea, but roughly 30-50% of patients cannot tolerate nightly mask use — and untreated sleep apnea carries real cardiovascular risks including arrhythmias, hypertension, and metabolic disease. For these patients, a range of evidence-based alternatives exist, and matching the right option to the individual physiology is what a sleep medicine specialist is trained to do.

This article draws on research from Babak Mokhlesi, MD, Division Chief of Pulmonary, Critical Care, and Sleep Medicine at Rush University Medical Center, who validated the STOP-Bang screening questionnaire and has published extensively on OSA epidemiology and metabolic consequences; Timothy Morgenthaler, MD, Professor of Medicine at Mayo Clinic, whose work defined complex sleep apnea syndrome and evaluated adaptive servoventilation; Reena Mehra, MD, Professor and Division Head at the University of Washington, whose nocturnal arrhythmia studies established the cardiovascular harm of untreated OSA; Jorge Mallea, MD, Consultant at Mayo Clinic Florida and co-author of practice parameters for central sleep apnea treatment; and Loutfi Aboussouan, MD, Associate Professor at Case Western Reserve University and Cleveland Clinic, who has studied the clinical predictors of hypercapnic respiratory failure in OSA.

How Common Is OSA — and Why Does Untreated Disease Matter?

Dr. Mokhlesi's population-based epidemiology paper (cited 510 times) estimated that OSA affects at least 15-24% of middle-aged men and 9-15% of women, with substantially higher rates in obese populations. These figures are likely underestimates given the proportion of undiagnosed cases.

The cardiovascular case for treating OSA is not theoretical. Dr. Mehra's landmark paper in the American Journal of Respiratory and Critical Care Medicine (cited 1,241 times) analyzed data from the Sleep Heart Health Study and found that sleep-disordered breathing events were strongly associated with nocturnal arrhythmias — including atrial fibrillation, non-sustained ventricular tachycardia, and complex ventricular ectopy. A subsequent analysis in the Journal of the American College of Cardiology (cited 286 times) showed that breathing events triggered arrhythmias with measurable temporal clustering. This is not incidental association — the hypoxemia and intrathoracic pressure swings from apnea events directly stress the cardiac conduction system.

Dr. Mokhlesi's CHEST Journal paper (cited 645 times) also found that patients with OSA have a significantly higher prevalence of type 2 diabetes and impaired glucose tolerance, mediated through intermittent hypoxia activating sympathetic pathways and disrupting cortisol rhythms. Untreated OSA is not a sleep quality problem — it is a cardiovascular and metabolic disease.

Why CPAP Fails — and What That Tells You About Alternatives

CPAP works by delivering a continuous positive pressure through a mask that mechanically prevents airway collapse during sleep. When it fails, the reason usually falls into one of several categories: mask leak, pressure intolerance, claustrophobia, positional discomfort, or emergence of central apneas. Understanding which failure mode applies guides which alternative is appropriate.

Complex sleep apnea syndrome — formally characterized by Dr. Morgenthaler in his 2006 SLEEP paper (cited 463 times) — is a condition in which obstructive apneas resolve on CPAP but central apneas emerge or persist. It occurs in approximately 15% of OSA patients placed on CPAP. It is not treatment failure in the usual sense; it represents a shift in the underlying apnea mechanism when the obstructive component is removed.

Oral Appliances: First-Line for Mild-to-Moderate OSA

Mandibular advancement devices (MADs) reposition the jaw and tongue forward during sleep, preventing soft tissue collapse. Multiple randomized trials show that properly fitted oral appliances reduce the apnea-hypopnea index (AHI) by 50% or more in most patients. For mild-to-moderate OSA, outcomes are comparable to CPAP for daytime sleepiness and blood pressure improvement, though CPAP typically achieves greater AHI reduction.

The key advantage of MADs is adherence: patients wear them approximately 6-7 hours per night compared to the 4-5 hours average for CPAP. Real-world effectiveness may therefore be comparable despite lower per-hour efficacy. AASM guidelines support oral appliances as a first-line option for mild OSA or for patients who prefer them over CPAP.

Oral appliances require fitting by a dentist trained in sleep medicine. They are not one-size-fits-all devices, and poorly fitted appliances can cause temporomandibular joint pain, tooth movement, and dry mouth.

Positional Therapy

For patients whose OSA is predominantly or exclusively positional — occurring mainly when sleeping supine — avoiding the back position reduces AHI by 50% or more. Approximately 25-50% of OSA patients have positional predominance. Confirmation requires a polysomnogram that records body position throughout the night.

Positional therapy devices range from the simple (a backpack with a tennis ball that makes supine sleeping uncomfortable) to the sophisticated (vibrotactile positional trainers that buzz when the patient rolls supine). The latter have shown efficacy in recent trials, though long-term adherence data are more limited than for CPAP or MADs.

Hypoglossal Nerve Stimulation (Inspire)

For patients with moderate-to-severe OSA who cannot tolerate CPAP, hypoglossal nerve stimulation is the most evidence-supported surgical alternative. The Inspire device, implanted subcutaneously, delivers mild electrical stimulation to the hypoglossal nerve timed with the breathing cycle, activating tongue musculature to prevent airway collapse.

The STAR trial showed a 68% median reduction in AHI and significant improvements in oxygen desaturation index at 12 months. Eligibility requires AHI of 15-65, BMI under 32, absence of complete concentric palatal collapse (assessed by drug-induced sleep endoscopy), and previous CPAP failure. The procedure requires general anesthesia and a 1-night hospital stay.

Adaptive Servoventilation (ASV) for Complex and Central Sleep Apnea

For patients with complex sleep apnea or predominant central apneas, Dr. Morgenthaler's group demonstrated in two controlled trials published in SLEEP and CHEST (cited 193 and 187 times respectively) that adaptive servoventilation outperforms CPAP and bilevel positive pressure for central event suppression. ASV uses a sophisticated algorithm to deliver pressure support that adapts breath-by-breath based on the patient's own ventilatory effort.

An important safety caveat: the SERVE-HF trial showed that ASV increased cardiovascular mortality in patients with central sleep apnea caused by reduced ejection fraction heart failure (EF below 45%). ASV is therefore contraindicated in this population. For patients with complex sleep apnea without heart failure, or with central apneas from other causes (opioids, post-stroke, idiopathic), ASV remains an appropriate and effective option.

Dr. Mallea's practice parameters paper on central sleep apnea treatment (cited 372 times) provides the comparative framework across ASV, bilevel ventilation, supplemental oxygen, and acetazolamide — the full spectrum of options for the challenging central apnea population.

Weight Loss and Bariatric Surgery

Obesity is the dominant modifiable risk factor for OSA. Substantial weight loss — whether through lifestyle modification, GLP-1 receptor agonist medications, or bariatric surgery — can significantly reduce AHI. In patients who undergo Roux-en-Y gastric bypass with average weight loss of 50-60% of excess body weight, resolution of OSA is documented in approximately 80% of cases.

Dr. Aboussouan's work on determinants of hypercapnia in obese OSA patients (cited 163 times) identified which patients with obesity-related sleep apnea are at risk of developing elevated daytime carbon dioxide — a complication requiring bilevel ventilation rather than CPAP. Weight loss reduces this risk directly by decreasing the mechanical load on the chest wall.

Questions to ask your doctor

• What is causing my CPAP intolerance — mask type, pressure, claustrophobia, or central apneas?
• Is my OSA positional, and if so, could positional therapy be my primary treatment?
• Do I qualify for hypoglossal nerve stimulation, and would I need a drug-induced sleep endoscopy first?
• If I have central or complex apneas, am I a candidate for adaptive servoventilation?
• Has my ejection fraction been checked, which would affect whether ASV is safe for me?
• How much would sustained weight loss improve my AHI?

The bottom line

CPAP failure does not mean sleep apnea cannot be treated — it means a different tool is needed. Oral appliances, positional therapy, hypoglossal nerve stimulation, and adaptive servoventilation each have strong evidence supporting their use in specific OSA subtypes. Untreated sleep apnea drives nocturnal arrhythmias, hypertension, insulin resistance, and daytime cognitive impairment that compound over years. A sleep medicine specialist can identify the physiological mechanism behind both your apnea and your CPAP failure, and match you to the intervention most likely to work.